These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36753693)

  • 1. Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties.
    Grasmeier MK; Weber S; Treiber M; Thaler MA; Luppa PB
    Clin Chem Lab Med; 2023 Jun; 61(7):1255-1265. PubMed ID: 36753693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients' sera.
    Beeg M; Burti C; Allocati E; Ciafardini C; Banzi R; Nobili A; Caprioli F; Garattini S; Gobbi M
    Sci Rep; 2021 Jul; 11(1):14976. PubMed ID: 34294782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoassay for Detection of Infliximab in Whole Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor.
    Lu J; Spasic D; Delport F; Van Stappen T; Detrez I; Daems D; Vermeire S; Gils A; Lammertyn J
    Anal Chem; 2017 Mar; 89(6):3664-3671. PubMed ID: 28222600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of Infliximab and Detection of Antidrug Antibodies in Serum by Use of Surface Plasmon Resonance.
    Thoren KL; Pasi B; Delgado JC; Wu AHB; Lynch KL
    J Appl Lab Med; 2018 Mar; 2(5):725-736. PubMed ID: 33636867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients.
    Lu J; Van Stappen T; Spasic D; Delport F; Vermeire S; Gils A; Lammertyn J
    Biosens Bioelectron; 2016 May; 79():173-9. PubMed ID: 26706938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab.
    Van den Bossche D; De Smet D; Debrabandere J; Vanpoucke H
    Clin Chem Lab Med; 2019 May; 57(6):856-863. PubMed ID: 30838834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.
    Laserna-Mendieta EJ; Salvador-Martín S; Marín-Jiménez I; Menchén LA; López-Cauce B; López-Fernández LA; Lucendo AJ
    J Pharm Biomed Anal; 2021 May; 198():114003. PubMed ID: 33714800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay.
    Weisshof R; Ungar B; Blatt A; Dahan A; Pressman S; Waterman M; Kopylov U; Ben-Horin S; Chowers Y
    Inflamm Bowel Dis; 2016 Jul; 22(7):1655-61. PubMed ID: 27120567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
    Jourdil JF; Némoz B; Gautier-Veyret E; Romero C; Stanke-Labesque F
    Ther Drug Monit; 2018 Aug; 40(4):417-424. PubMed ID: 29608486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
    Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
    Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays.
    Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Coelho R; Tavares P; Soares J; Sousa AL; Carvalho D; Sousa P; da Silva JP; Meira T; Silva Ferreira F; Dias CC; Chowers Y; Ben-Horin S; Magro F;
    Therap Adv Gastroenterol; 2016 Nov; 9(6):781-794. PubMed ID: 27803733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
    Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
    AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.
    Schmitz EM; van de Kerkhof D; Hamann D; van Dongen JL; Kuijper PH; Brunsveld L; Scharnhorst V; Broeren MA
    Clin Chem Lab Med; 2016 Jul; 54(7):1211-9. PubMed ID: 26587745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
    Teixeira FV; Sassaki LY; Saad-Hossne R; Baima JP; Magro DO; Coy CSR; Kotze PG
    Arq Gastroenterol; 2018; 55(2):192-197. PubMed ID: 30043873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
    Valor L; Hernández-Flórez D; de la Torre I; Llinares F; Rosas J; Yagüe J; Garrido J; Naredo E
    Clin Exp Rheumatol; 2015; 33(5):617-23. PubMed ID: 26316061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
    Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
    Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution.
    Vultaggio A; Nencini F; Carraresi A; Pratesi S; Movérare R; Eriksson C; Venemalm L; Maggi E; Matucci A
    Allergy; 2018 Nov; 73(11):2172-2181. PubMed ID: 29719053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease.
    Dorn-Rasmussen M; Buhl S; Brynskov J; Bay JT; Bolstad N; Klausen TW; Warren DJ; Ainsworth MA; Steenholdt C
    Ther Drug Monit; 2022 Apr; 44(2):290-300. PubMed ID: 34387220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.